Assembly Biosciences Inc ( (ASMB) ) has released its Q1 earnings. Here is a breakdown of the information Assembly Biosciences Inc presented to its investors.
Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics targeting serious viral diseases, with a pipeline that includes clinical-stage investigational therapies for conditions such as recurrent genital herpes and hepatitis B virus. In its latest earnings report for the first quarter of 2025, Assembly Biosciences reported collaboration revenue of $9.4 million, an increase from $5.8 million in the same period last year, primarily due to its partnership with Gilead Sciences. The company incurred a net loss of $8.8 million, slightly less than the $9.1 million loss in the previous year, reflecting ongoing investments in research and development, which rose to $14.9 million from $11.9 million. Despite the losses, Assembly Biosciences maintains a strong cash position with $23.4 million in cash and cash equivalents, although this is a decrease from $38.3 million at the end of 2024. Looking ahead, Assembly Biosciences remains focused on advancing its clinical programs and leveraging its collaboration with Gilead to support its development pipeline, aiming to bring new treatments to market in the coming years.